Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial.

Saved in:
Bibliographic Details
Title: Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial.
Authors: Kelly E; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Greenland M; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., de Whalley P; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Macaulay GC; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Aley PK; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Plested E; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Koleva S; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Cotton J; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Kinch J; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Madupuri T; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Read RC; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Ramsay M; Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, UK., Cameron C; Health Protection Scotland, Glasgow, UK., Turner DPJ; University of Nottingham, UK; Nottingham University Hospitals NHS Trust, Nottingham, UK., Heath P; Vaccine Institute, St. George's, University of London and St. George's University Hospitals NHS Trust, London, UK., Connor P; Noah's Ark Children's Hospital for Wales, University Hospital of Wales, Cardiff, UK., Cathie K; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Faust SN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Banerjee I; Royal Manchester Children's Hospital, Manchester University Hospitals Foundation Trust, UK., Man K; Royal Free Hospital NHS Foundation Trust, London, UK., Shackley F; Sheffield's Children NHS Foundation Trust, Sheffield, UK., O' Riordan S; Leeds Teaching Hospital NHS Foundation Trust, Leeds, UK., Owens S; Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK., Polychronakis T; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Trari Belhadef H; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Mujadidi Y; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Singha A; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Cantrell L; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Clutterbuck E; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Anslow R; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., James T; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Hallis B; UK Health Security Agency, Porton Down, Salisbury, UK., Matheson M; UK Health Security Agency, Porton Down, Salisbury, UK., Chang L; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Lambe T; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute, University of Oxford, Oxford, UK., Nguyen-Van-Tam JS; Population and Lifespan Health, University of Nottingham, Nottingham, UK., Snape MD; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Minassian AM; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK., Liu X; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK. Electronic address: Xinxue.liu@paediatrics.ox.ac.uk.
Source: The Journal of infection [J Infect] 2026 Jan; Vol. 92 (1), pp. 106663. Date of Electronic Publication: 2025 Dec 01.
Publication Type: Clinical Trial, Phase II; Equivalence Trial; Journal Article; Multicenter Study
Journal Info: Publisher: W.B. Saunders Country of Publication: England NLM ID: 7908424 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2742 (Electronic) Linking ISSN: 01634453 NLM ISO Abbreviation: J Infect Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1532-2742
DOI:10.1016/j.jinf.2025.106663